Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis
SCD
1 other identifier
interventional
9
1 country
1
Brief Summary
The aim of this study is to determine the tolerability and potential efficacy of dietary therapy, the Specific Carbohydrate Diet (SCD), in pediatric patients with Crohn's disease (CD) and Ulcerative Colitis (UC). This is a single center, open labelled study designed to determine tolerability, preliminary safety and potential efficacy in pediatric patients with CD and UC. The study patients will be recruited from Seattle Children's GI clinic. the investigators will enroll 10 patients with mild to moderate CD (defined as PCDAI score of 10-29) or Ulcerative colitis (PUCAI 10-60) ages 8 to 21 years. Each patient will be in the study for approximately 12 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
August 4, 2014
CompletedFirst Posted
Study publicly available on registry
August 12, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2017
CompletedMay 24, 2019
May 1, 2018
3.3 years
August 4, 2014
May 22, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Pediatric Crohn's disease Activity Index/Pediatric Ulcerative Colitis Activity Index at baseline and 12 weeks
Pediatric Crohn's disease Activity Index/Pediatric Ulcerative Colitis Activity Index are validated measures of disease activity for pediatric Crohn's disease and ulcerative colitis respectively.
12 Week
Secondary Outcomes (1)
Change of common Laboratory measures including Complete Blood Count, sedimentation rate, C-Reactive Protein, stool Calprotectin at baseline and 12 weeks
12 weeks
Other Outcomes (1)
Stool Microbiome Analysis from baseline and 12 weeks
12 Weeks
Study Arms (1)
Specific Carbohydrate diet (SCD)
EXPERIMENTALThe treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include "Breaking the Vicious Cycle" by Elaine Gottschall and "Recipes for the Specific Carbohydrate Diet" by Raman Prasad.
Interventions
Eligibility Criteria
You may qualify if:
- Children and adolescents eight to twenty one years old
- Diagnosis of Ulcerative colitis or Crohn's Disease made by a primary gastroenterologist based upon history, physical exam, laboratory/radiological studies and gastrointestinal histology
- Mild or moderate disease activity based upon PCDAI score (10-45) or PUCAI score (10-60)
- Parent/guardian and child must be able to comprehend the consent and assent
- Parent/guardian and participant must be able to attend study visits at baseline, and weeks +2, +4, +8, +12.
- Patient must not have medication changes for his/her inflammatory bowel disease medications for at least 1 months, unless medically necessary.
You may not qualify if:
- Severe disease with PCDAI \>45 or PUCAI \>60
- Active or history of intraabdominal abscess, intraabdominal fistula, stricturing Crohn's disease
- Other serious medical conditions such as neurological, liver, kidney, autoimmune or systemic disease.
- Has begun TNF inhibitors within two months prior to study
- Has had change of maintenance medication within the last month
- Tobacco, alcohol or illicit drug abuse
- Pregnant subject recipients will be excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- David Suskindlead
Study Sites (1)
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Related Publications (2)
Suskind DL, Wahbeh G, Gregory N, Vendettuoli H, Christie D. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):87-91. doi: 10.1097/MPG.0000000000000103.
PMID: 24048168BACKGROUNDBraly K, Williamson N, Shaffer ML, Lee D, Wahbeh G, Klein J, Giefer M, Suskind DL. Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):533-538. doi: 10.1097/MPG.0000000000001613.
PMID: 28825603DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David L Suskind, MD
Seattle Children's Hospital and The University of Washington
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Pediatrics
Study Record Dates
First Submitted
August 4, 2014
First Posted
August 12, 2014
Study Start
June 1, 2014
Primary Completion
September 1, 2017
Study Completion
September 1, 2017
Last Updated
May 24, 2019
Record last verified: 2018-05
Data Sharing
- IPD Sharing
- Will not share
Not discussed